NetworkNewsBreaks – InMed Pharmaceuticals, Inc.
Post# of 229
(Total Views: 1031)
Posted On: 10/10/2017 6:05:08 PM
NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Addition of Dr. Mauro Maccarrone to Scientific Advisory Board
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the addition of Dr. Mauro Maccarrone to its scientific advisory board. Maccarrone is professor and chair of biochemistry and molecular biology at Campus Bio-Medico, University of Rome. He also serves as director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome. “InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs. One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their in-depth knowledge to help advance our products,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “We are very pleased to add Dr. Mauro Maccarrone and his vast experience in the field of cannabinoid research as an integral part of our Scientific Advisory Board. We look forward to working with Dr. Maccarrone to help bring drug therapies to those in need.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the addition of Dr. Mauro Maccarrone to its scientific advisory board. Maccarrone is professor and chair of biochemistry and molecular biology at Campus Bio-Medico, University of Rome. He also serves as director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome. “InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs. One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their in-depth knowledge to help advance our products,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “We are very pleased to add Dr. Mauro Maccarrone and his vast experience in the field of cannabinoid research as an integral part of our Scientific Advisory Board. We look forward to working with Dr. Maccarrone to help bring drug therapies to those in need.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)